| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 03/18/2004 | US20040053838 Measuring serum IGF-I and/or IGF-I binding protein levels after birth of patient to obtain IGF-I or IGF-I binding protein level and correlating said level with in utero baseline level based on gestational age matched mean levels |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053820 Histone deacetylase inhibitor |
| 03/18/2004 | US20040053819 Normalizing blood glucose levels by maintaining chronic steady state plasma levels of 60-200 picomoles/liter; subcutaneous injection 1-2 times every 24 hours |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053228 Apoptosis inhibitory polypeptides, gene and polynucleotide encoding it and compositions containing the same |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052866 Administering gaseous carbon monoxide; also for treatment of alcoholism |
| 03/18/2004 | US20040052818 Flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy terminal hydrophobic region is not affected by the deletion |
| 03/18/2004 | US20040052813 Polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits and the diagnostic kits |
| 03/18/2004 | US20040052796 Anticancer agents; antitumor agents; controlling gene expression; quantitative analysis |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497989A1 Probiotic bacterium: lactobacillus fermentum |
| 03/18/2004 | CA2497972A1 Hbv precore protein having a particle-forming ability |
| 03/18/2004 | CA2497955A1 Medicament for preventing and/or treating inflammatory bowel disease |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2495939A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/17/2004 | EP1398369A1 Bifidobacteria and preparations containing them |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1397683A2 Methods for identifying compounds for treatment of ibd |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397366A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397358A1 Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/17/2004 | EP1397357A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397354A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 03/17/2004 | EP1397351A1 Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397154A2 Abin-mediated hepatitis protection |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397147A1 Use of adenosine a1 agonists in the treatment of emesis |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397133A1 Rapid onset formulation |
| 03/17/2004 | EP1397131A1 Compositions comprising nitrofurantoin and uva ursi |
| 03/17/2004 | EP1397127A1 Solid pharmaceutucal formulations comprising modafinil |
| 03/17/2004 | EP1397106A1 Dental restorative materials |
| 03/17/2004 | EP1397105A1 Methods for inhibiting angiogenesis |
| 03/17/2004 | EP1397044A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| 03/17/2004 | EP1244434B1 Use of chemotherapeutic agents |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |
| 03/17/2004 | EP1224175B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 03/17/2004 | EP1147102B1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 03/17/2004 | EP1144413B1 2,5-diazabicyclo 2.2.1]heptane derivatives, their preparation and therapeutic uses |
| 03/17/2004 | EP1144365B1 Inhibitors of alpha-4 beta-1 mediated cell adhesion |
| 03/17/2004 | EP1100792B1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP0891362B1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 03/17/2004 | EP0891332B1 6-phenylpyridyl-2-amine derivatives |
| 03/17/2004 | CN1483035A Sulfamidothienopyrimidines |
| 03/17/2004 | CN1483034A Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| 03/17/2004 | CN1483032A Process for making substituted 8-arylquinolinium benzenesulfonate |
| 03/17/2004 | CN1483030A Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for the treatment of nervous system disorders |
| 03/17/2004 | CN1483029A Sodium channel modulators derived from 2-piperidylimidazoles |
| 03/17/2004 | CN1483026A Benzoylpyridazine |
| 03/17/2004 | CN1483024A Vla-4 inhibitors |
| 03/17/2004 | CN1483023A 3-arylindole derivatives and their use as cb2 receptor agonists |
| 03/17/2004 | CN1483021A Novel 1, 2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 03/17/2004 | CN1482918A Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 03/17/2004 | CN1482917A New therapeutic uses of smr1 peptides |
| 03/17/2004 | CN1482916A Vaccine composite containing invert growth factor a |
| 03/17/2004 | CN1482914A Remedies for hepatitis c |
| 03/17/2004 | CN1482910A Famotidine injections |
| 03/17/2004 | CN1482905A Compositions for oral use |
| 03/17/2004 | CN1482902A Inhibitor for the production of tnf alpha |
| 03/17/2004 | CN1482247A Non-antibiotics resistant shuttle plasmid expression carrier and its constructing method and uses |
| 03/17/2004 | CN1482231A Ampelopsin healthcare wine |
| 03/17/2004 | CN1482141A Method for preparing specific composite IgY against periodontal disease and group system thereof |
| 03/17/2004 | CN1482140A Process for extracting medicinal protein from ostrich blood and use thereof |
| 03/17/2004 | CN1481897A Biotechnological formulation for suppressing and killing helicobacter pylori, its preparation and use |
| 03/17/2004 | CN1481889A Water-purging pill comprising genkwanin and kansui root |
| 03/17/2004 | CN1481878A Medication for curing aphtha |
| 03/17/2004 | CN1481877A A compound Chinese herb composition, its preparation method and use |
| 03/17/2004 | CN1481876A Medication for virus hepatitis and hepatocirrhosis |
| 03/17/2004 | CN1481874A Capsule for fortifying kidney and nourishing qi and its preparation mehtod |
| 03/17/2004 | CN1481873A Novel preparation method for ageratum zhengqi capsule |
| 03/17/2004 | CN1481871A Compound Chinese traditional medicine formulation for hepatitis B and its preparation method |
| 03/17/2004 | CN1481870A Compound Chinese traditional medicine formulation for chronic and stubborn constipation |
| 03/17/2004 | CN1481869A Icterus-curing capsule for hepatitis B and its preparation method |
| 03/17/2004 | CN1481868A Novel use of prepared Chinese traditional medicine liushen pill |
| 03/17/2004 | CN1481862A Chinese traditional medicine composition curing viscera inflammation, toxin and endocrine disorder |
| 03/17/2004 | CN1481860A Medication for detoxifying and nourishing saliva and qi |
| 03/17/2004 | CN1481858A Preparation method of glabrous sarcandra herb capsule |
| 03/17/2004 | CN1481855A Yunan red drug tablet , its preparation method and use |
| 03/17/2004 | CN1481854A Delay, control release drug of prepared aconite root which can regulate the function of middle-warmer, and its preparation method |
| 03/17/2004 | CN1481852A Healthcare wine for fortifying kidney and strengthening the male function and its preparation method |
| 03/17/2004 | CN1481848A Anti-age capsule |
| 03/17/2004 | CN1481847A Anti-age dan formulation |